Oncolytics Biotech Inc. ONCY
Set alert
0.43 USD 0.00 -0.54%
At close · Oct 30
0.42 -0.01 -1.27%
After hours · Oct 30, 4:09 PM ET
0.405 Day range 0.4298
0.4254 52-week range 1.27
- YTD
- -51.10%
- 1 year
- -63.33%
- Open
- 0.4207
- Prev close
- 0.4277
- Mkt cap
- 55.78M
- Vol
- 764.33K
- Avg vol
- 1.04M
- EPS
- -0.35
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.405
- High
- 0.4298
- Forward P/E
- -3.02
- Beta
- 1.51
- Short ratio
- 3.51
- Inst. own
- 1.76%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.04
- 200-d avg
- 1.04
- 1y target
- 4.85
2Y chart
Events in this range
- Nov 12, 2024Earnings: -0.09; estimate -0.08; surprise -12.5%
- Nov 14, 2024Rating: HC Wainwright & Co. · Buy → Buy
Signals (99)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Oct 29, 2026 | 2 days ago |
| RSI: Oversold | Oct 26, 2026 | 5 days ago |
| MACD: Buy Signal | Oct 22, 2026 | 1 week ago |
| RSI: Oversold | Oct 1, 2026 | 1 month ago |
| RSI: Oversold | Sep 23, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 8, 2026 | 1 month ago |
| SMA: Bearish | Sep 4, 2026 | 1 month ago |
| SMA: Bullish | Sep 2, 2026 | 1 month ago |
| SMA: Bearish | Aug 31, 2026 | 2 months ago |
| SMA: Bullish | Aug 28, 2026 | 2 months ago |
| SMA: Bearish | Aug 27, 2026 | 2 months ago |
| SMA: Bullish | Aug 25, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 7, 2026 | 2 months ago |
| SMA: Bearish | Jul 16, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 16, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 15, 2026 | 3 months ago |
| SMA: Bullish | Jul 9, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 6, 2026 | 3 months ago |
| SMA: Bearish | Jul 1, 2026 | 4 months ago |
| SMA: Bullish | Jun 25, 2026 | 4 months ago |
| SMA: Bearish | Jun 24, 2026 | 4 months ago |
| SMA: Bullish | Jun 23, 2026 | 4 months ago |
| SMA: Bearish | Jun 22, 2026 | 4 months ago |
| SMA: Bullish | Jun 16, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 16, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 9, 2026 | 4 months ago |
| SMA: Bearish | Jun 2, 2026 | 5 months ago |
| SMA: Bearish | Jun 2, 2026 | 5 months ago |
| SMA: Bullish | May 28, 2026 | 5 months ago |
| MACD: Buy Signal | May 27, 2026 | 5 months ago |
| SMA: Bearish | Apr 27, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 27, 2026 | 6 months ago |
| SMA: Bearish | Apr 24, 2026 | 6 months ago |
| SMA: Bullish | Apr 15, 2026 | 6 months ago |
| SMA: Bullish | Apr 13, 2026 | 6 months ago |
| SMA: Bearish | Apr 10, 2026 | 6 months ago |
| SMA: Bullish | Apr 9, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 6, 2026 | 6 months ago |
| MACD: Sell Signal | Mar 10, 2026 | 7 months ago |
| SMA: Bullish | Feb 23, 2026 | 8 months ago |
| SMA: Bullish | Feb 23, 2026 | 8 months ago |
| SMA: Bearish | Feb 20, 2026 | 8 months ago |
| SMA: Bearish | Feb 20, 2026 | 8 months ago |
| SMA: Bullish | Feb 18, 2026 | 8 months ago |
| SMA: Bearish | Feb 17, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 17, 2026 | 8 months ago |
| SMA: Bullish | Feb 13, 2026 | 8 months ago |
| SMA: Bullish | Feb 13, 2026 | 8 months ago |
| SMA: Bearish | Feb 3, 2026 | 9 months ago |
| SMA: Bearish | Jan 30, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 30, 2026 | 9 months ago |
| RSI: Overbought | Jan 22, 2026 | 9 months ago |
| SMA: Bullish | Jan 21, 2026 | 9 months ago |
| SMA: Bearish | Jan 20, 2026 | 9 months ago |
| SMA: Bullish | Jan 16, 2026 | 9 months ago |
| SMA: Bearish | Jan 15, 2026 | 9 months ago |
| SMA: Bullish | Jan 13, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 5, 2026 | 9 months ago |
| SMA: Bullish | Jan 2, 2026 | 10 months ago |
| SMA: Bearish | Dec 30, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 29, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 9, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 8, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 5, 2025 | 11 months ago |
| MACD: Sell Signal | Dec 1, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 25, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 20, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 19, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 18, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 12, 2025 | 11 months ago |
| RSI: Oversold | Nov 4, 2025 | 12 months ago |
| SMA: Bearish | Oct 16, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 6, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 30, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 24, 2025 | 1 year ago |
| RSI: Overbought | Sep 9, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 21, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 23, 2025 | 1 year ago |
| RSI: Overbought | Jul 16, 2025 | 1 year ago |
| RSI: Overbought | Jul 2, 2025 | 1 year ago |
| RSI: Overbought | Jun 27, 2025 | 1 year ago |
| RSI: Overbought | Jun 13, 2025 | 1 year ago |
| SMA: Bullish | Jun 11, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 9, 2025 | 1 year ago |
| RSI: Oversold | May 27, 2025 | 1 year ago |
| RSI: Oversold | May 20, 2025 | 1 year ago |
| MACD: Sell Signal | May 6, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 11, 2025 | 1 year ago |
| RSI: Oversold | Apr 8, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 31, 2025 | 1 year ago |
| RSI: Oversold | Mar 31, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 21, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 11, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 5, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 25, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 6, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 13, 2025 | 1 year ago |
| MACD: Buy Signal | Dec 19, 2024 | 1 year ago |
| RSI: Oversold | Dec 3, 2024 | 1 year ago |
Key statistics
- Market cap
- 69.81M
- Enterprise value
- 55.56M
- Trailing P/E
- 0.00
- Forward P/E
- -3.02
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 2.45
- EPS (TTM)
- -0.25
- Beta
- 1.51
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -15.77M
- Total cash
- 24.85M
- Total debt
- 1.12M
- Return on equity
- -138.22%
- Shares outstanding
- 77.07M
- Short % of float
- 3.89%
- 50-day average
- 1.04
- 200-day average
- 1.04
Analyst view
Consensus: none
Price target (mean) 4.85
Ratings (0m) 8 8 buy · 0 hold · 0 sell
- Strong buy5
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.1345.
Financials — quick view
ONCY Revenue — quarterly 0
ONCY Net income — quarterly -9.44M
ONCY EPS — quarterly -0.08
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.08 | -0.09 | -0.01 | -12.50% |
| Aug 1, 2024 | Jun 1, 2024 | -0.08 | -0.07 | +0.01 | +12.50% |
| May 9, 2024 | Mar 1, 2024 | -0.09 | -0.07 | +0.02 | +22.22% |
| Mar 7, 2024 | Dec 1, 2023 | -0.11 | -0.04 | +0.07 | +63.64% |
| Nov 3, 2023 | Sep 1, 2023 | -0.07 | -0.10 | -0.03 | -42.86% |
| Aug 14, 2023 | Jun 1, 2023 | -0.09 | -0.09 | 0.00 | 0.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 19, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 21, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Apr 4, 2024 | Raymond James | init | — | Outperform |
| Mar 8, 2024 | HC Wainwright & Co. | main | Buy | Buy |
About Oncolytics Biotech Inc.
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- oncolyticsbiotech.com
News
- Oncolytics Biotech Announces Its Group 4 Of Phase 1/2 GOBLET Trial Of Pelareorep In Combination With Atezolizumab Failed to Reach Median Overall Survival
- Oncolytics Biotech® Reports Strong Durability and Survival Data in Anal Cancer, Positioning Pelareorep as Potential Backbone Immunotherapy Across HPV-Driven Cancers
- Oncolytics Biotech To Present Trail-In-Progress Abstract, E-Poster For Its REO 033 Trial At European Society For Medical Oncology
- Oncolytics Biotech® to Present REO 033 Trial in Progress Abstract at ESMO Showcasing Pelareorep's Potential in Colorectal Cancer
- Oncolytics Biotech Anticipates Reporting Final Results From Group 4 Of Its GOBLET Phase 1/2 Trial In Q4 For Pelareorep With Atezolizumab To Treat Squamous Cell Anal Carcinoma; To Receive Payment Under Grant From Pancreatic Cancer Action Network This Quarter
- Oncolytics Biotech® Provides Update on GOBLET Study Clinical Data and Final PanCAN Grant Payment
- Oncolytics Biotech Expands Pelareorep Patent Protection Strategy Through 2044
- Oncolytics Biotech® Secures Patent Protection to Late 2040s and Provides Intellectual Property Portfolio Update
- Oncolytics Biotech Publishes Data On Pelareorep Immunotherapy In Proceedings Of The National Academy Of Sciences
- Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy
Your note
Sign in to keep a note on ONCY — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| International Assets Investment Management, LLC | 0.26% | 198,400 | 179.71K | Jun 29, 2024 |
| Seeds Investor LLC | 0.25% | 189,941 | 172.05K | Sep 29, 2024 |
| Goldman Sachs Group Inc | 0.11% | 84,998 | 76.99K | Sep 29, 2024 |
| Royal Bank of Canada | 0.10% | 74,546 | 67.52K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.10% | 79,249 | 71.78K | Sep 29, 2024 |
| Commonwealth Equity Services, LLC | 0.08% | 61,114 | 55.36K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.05% | 41,942 | 37.99K | Oct 30, 2024 |